- AbbVie Inc ABBV and Immunome Inc IMNM announced a worldwide collaboration and option agreement to discover up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome's Discovery Engine.
- Immunome will receive an upfront payment of $30 million. It will be eligible to receive additional platform access payments in the aggregate amount of up to $70 million based on AbbVie's election for Immunome to continue research using its Discovery Engine.
- Related: Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants.
- Immunome is also eligible to receive development and first commercial sale milestones of up to $120 million per target with respect to certain products derived from target-antibody pairs that AbbVie elects to purchase, with potential for further sales-based milestones as well as tiered royalties on global sales.
- Price Action: IMNM shares are up 5.52% at $4.97 on the last check Friday.
Loading...
Loading...
IMNMImmunome Inc
$8.76-2.12%
Edge Rankings
Momentum
14.34
Growth
Not Available
Quality
Not Available
Value
8.47
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in